Application Note: Anti-NFkB p65 (Rel A) is tested by immunoblot of human and mouse NFkB p65 (Rel A), immunohistochemistry, and ELISA. This product was also tested in a gel supershift assay, IP, IF, and ChIP and found to be reactive against all p65 (Rel A) containing human, mouse or rat NFkB complexes using 0.5 to 1.0 µl per assay.
Concentration Value: 80 mg/mL
ELISA Dilution: 1:5,000
ChIP Dilution: 1 μl/IP
Gel Shift Dilution: 05 µL - 1.0 µL
Immunohistochemistry Dilution: 1:400
IF Microscopy Dilution: User Optimized
Immunoprecipitation Dilution: User Optimized
Western Blot Dilution: 1:2,000 - 1:5,000
General Disclaimer Note: This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
Immunogen: NFkB p65 (Rel A) peptide corresponding to a region near the C-terminus of the human protein conjugated to Keyhole Limpet Hemocyanin (KLH).
Physical State: Liquid (sterile filtered)
Purity and Specificity: NFkB p65 (Rel A) was prepared from monospecific antiserum by delipidation and defibrination. Anti-NFkB p65 (Rel A) may react non-specifically with other proteins. Control peptide (code #100-4165p) will compete only with the specific reaction of antiserum with the NFkB p65 (Rel A) subunit.
Background: Anti-NFkB p65 Antibody recognizes NFKB p65 which is a component of NFKB. NFKB was originally identified as a factor that binds to the immunoglobulin kappa light chain enhancer in B cells. It was subsequently found in non-B cells in an inactive cytoplasmic form consisting of NFkappaB bound to IkappaB. NFkappaB was originally identified as a heterodimeric DNA binding protein complex consisting of p65 (RelA) and p50 (NFKB1) subunits. Other identified subunits include p52 (NFKB2), c-Rel, and RelB. The p65, cRel, and RelB subunits are responsible for transactivation. The p50 and p52 subunits possess DNA binding activity but limited ability to transactivate. p52 has been reported to form transcriptionally active heterodimers with the NFkappaB subunit p65, similar to p50/p65 heterodimers. The heterodimers of p52/p65 and p50/p65 are regulated by physical inactivation in the cytoplasm by IkappaBalpha. IkappaBalpha-binds to the p65 subunit, preventing nuclear localization and DNA binding. Low levels of p52 and p50 homodimers can also exist in cells.
Low Endotoxin: No
Other: User Optimized
English
Deutsch
